Sex differences in cardiotoxicity of anaplastic lymphoma kinase inhibitors: An analysis of the FDA Adverse Event Reporting System
{{output}}
Introduction: Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have transformed the management of ALK-rearranged non-small-cell lung cancer (NSCLC), yet their cardiotoxicity profile remains incompletely characteri... ...
